查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018931

人用狂犬疫苗市場：2026-2032年全球市場預測（依疫苗類型、疫苗分類、給藥途徑、製劑、通路及最終用戶分類）

Human Rabies Vaccines Market by Vaccine Type, Vaccine Class, Route Of Administration, Formulation, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年人類狂犬病疫苗市場價值11億美元，預計2026年將成長至11.5億美元，複合年成長率為4.76%，到2032年將達到15.2億美元。

主要市場統計數據
基準年 2025 11億美元
預計年份：2026年 11.5億美元
預測年份：2032年 15.2億美元
複合年成長率 (%) 4.76%

人類狂犬病疫苗的策略部署：重點關注臨床緊迫性、近期技術進步以及影響相關人員決策的政策重點。

人類用狂犬病疫苗仍然是全球公共衛生對抗狂犬病工作的基石，一旦出現臨床症狀，狂犬病幾乎必然致命。免疫學、生產平台和接種技術的進步提高了疫苗的安全性和物流可行性，但疫苗取得、公眾意識和低溫運輸基礎設施方面的持續差異導致不同地區疫苗保護程度參差不齊。臨床需求顯而易見：透過接種疫苗和及時進行暴露後預防是預防死亡和控制感染傳播的最有效手段。

科學創新、供應鏈最佳化和跨部門夥伴關係如何改變全球人類狂犬病疫苗接種的格局和專案優先事項？

人類狂犬病疫苗領域正經歷一場變革，其驅動力來自科學創新、方案最佳化以及不斷發展的供應鏈生態系統。新型生產技術和細胞基材技術的進步降低了疫苗的反應原性，並穩定了抗原品質。加之法規結構的強化，多個地區的核准流程正在加速推進。同時，皮內注射和減量接種方案的引入，透過提高成本效益和擴大現有疫苗覆蓋人群，正在重塑免疫接種方案。

評估 2025 年美國關稅變化對人類狂犬病疫苗供應鏈、籌資策略和本地化決策的影響。

美國近期就2025年即將生效的關稅談判和貿易政策調整，為狂犬病疫苗的生產、採購和分銷帶來了新的考量。關稅可能影響進口原料、生技藥品和成品疫苗的下游成本，進而影響公共衛生機構和私人經銷商的籌資策略。如果關稅導致投入成本上升，製造商可能需要調整籌資策略，推進關鍵生產環節的本地化，或與供應商重新談判合約條款，以確保利潤率和維持供應穩定性。

針對每種疫苗類型、分類、給藥途徑、配方、最終用戶和分銷管道，制定臨床引進和商業策略的細分市場洞察。

細分市場分析揭示了每種疫苗類型、分類、給藥途徑、製劑、最終用戶和分銷管道的不同需求促進因素、臨床考慮和商業性管道。依疫苗類型分析顯示，暴露後預防和暴露前預防在操作上有明顯差異。暴露後預防計畫優先考慮快速取得、緊急物流以及與創傷護理和免疫球蛋白療法的整合，而暴露前預防計畫則著重於針對高風險族群的定向宣傳活動和職業免疫接種計畫。疫苗分類揭示了源自人類二倍體細胞、純化雞胚細胞和純化Vero細胞的疫苗之間的差異，這些差異會影響區域耐受性、生產規模化和監管熟悉程度，進而影響疫苗的普及曲線和採購偏好。

流行病學、法規結構和供給能力的區域差異決定了重點地區疫苗部署策略的差異化。

區域趨勢導致疾病負擔、監管管道和供應系統能力有顯著差異，這些差異決定了疫苗部署的策略重點。在美洲，公共衛生計畫和國家免疫規劃通常優先考慮快速反應能力和與緊急服務的協調，而集中式政府競標和分散式醫療保健系統的採購框架也存在差異，這影響著供應商的參與和合約簽訂方式。在歐洲、中東和非洲，協調監管的努力與基礎設施成熟度的差異並存。有些市場擁有先進的低溫運輸網路和藥品安全監測系統，而有些市場則需要投資於培訓和最後一公里物流以擴大覆蓋範圍。

每家公司在生產製造、臨床開發和服務導向商業模式方面的策略如何影響狂犬病疫苗的競爭優勢和供應可靠性？

了解公司層面的發展趨勢對於掌握人用狂犬病疫苗領域的創新管線、生產能力和商業性化進程至關重要。主要企業正投資於製程改進、細胞基材最佳化和品管系統，以提高產量和產品一致性。先行生產商與區域契約製造生產商之間的策略合作，有助於擴大生產規模、加速市場准入，同時也能應對多個司法管轄區的監管核准。此外，多家機構正在推動臨床研究，以最佳化給藥方案並評估不同族群的免疫抗原性，從而兼顧安全性和計畫可行性。

與製造商、採購負責人和公共衛生領導人一起採用切實可行的高優先級建議，以增強供應韌性、提高專案效率並公平獲得狂犬病疫苗。

產業領導者應優先致力於增強供應韌性、提高專案效率並加快人用狂犬病疫苗的公平獲取。首先，投資於生產冗餘和區域生產夥伴關係將有助於降低貿易相關成本衝擊的影響，並提高前置作業時間的可預測性。其次，加強醫護人員皮內注射的訓練（皮內注射可節省劑量），並統一各轄區的臨床指南，將有助於擴大疫苗接種覆蓋範圍，同時有效管理耗材使用和低溫運輸負荷。第三，銷售部門應與公共衛生機構合作，推動聯合採購協議和共同採購機制，以穩定需求並促進長期生產能力的投資。

我們採用嚴謹的多面向調查方法，結合專家訪談、監管機構審查和實際案例研究分析，為決策者提供了切實可行的見解。

本執行摘要的研究基礎建構了一個多方面的證據庫，該證據庫結合了對關鍵相關人員的訪談、同行評審的科學文獻、監管文件和營運案例研究。主要研究包括對臨床專家、供應鏈經理、採購負責人和銷售主管的訪談，以了解實際營運、臨床偏好和合約慣例。二級資訊來源包括監管指南、疫苗生產技術專著以及已發表的關於給藥策略和免疫抗原性的研究，這些資料與不同醫療保健系統的專案營運經驗相結合。

總結了科學進展、專案重點和策略挑戰，以加快有效進行狂犬病預防和控制活動。

本執行摘要概述了參與透過疫苗接種策略預防和控制人類狂犬病的相關人員需要考慮的關鍵因素。科學進步和供應鏈創新為擴大疫苗接種覆蓋範圍提供了明確的機遇，但要實現這些機遇，需要在生產、採購和臨床實踐等各個環節開展協調一致的努力。關稅和貿易的考量凸顯了全球供應鏈網路的脆弱性，以及風險意識採購和區域間生產合作的重要性。針對各個環節的分析揭示了臨床方案、製劑選擇和分銷管道如何相互作用並影響項目的可行性和推廣。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：人用狂犬疫苗市場：依疫苗類型分類

  • 暴露後預防
  • 暴露前預防

第9章：人用狂犬疫苗市場：依疫苗分類

  • 人類二倍體細胞
  • 純化的雞胚細胞
  • 純化的Vero細胞

第10章：人用狂犬疫苗市場：依給藥途徑分類

  • 皮內注射
  • 肌肉內部

第11章 人類狂犬病疫苗市場：以劑型分類

  • 液體
  • 冷凍乾燥

第12章 人類狂犬疫苗市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：人用狂犬疫苗市場：依最終用戶分類

  • 診所
  • 醫院
  • 研究機構

第14章 人類狂犬病疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 人類狂犬病疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 人類狂犬病疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國狂犬病疫苗市場

第18章：中國狂犬病疫苗市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bavarian Nordic A/S
  • Beijing Minhai BIoTechnology Co., Ltd.
  • Bharat BIoTech International Limited
  • Bio-Med Pvt. Ltd.
  • Cadila Healthcare Ltd.
  • Changchun Institute of Biological Products Co., Ltd.
  • Chengda BIoTechnology Co., Ltd.
  • China National Pharmaceutical Group Co., Ltd.
  • GlaxoSmithKline plc
  • Hualan Biological Engineering Inc.
  • Indian Immunologicals Limited
  • Medigen BIoTechnology Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • PT Bio Farma（Persero）Tbk
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • Sinovac BIoTech Ltd.
  • Valneva SE
Product Code: MRR-710B1F0AC439

The Human Rabies Vaccines Market was valued at USD 1.10 billion in 2025 and is projected to grow to USD 1.15 billion in 2026, with a CAGR of 4.76%, reaching USD 1.52 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.10 billion
Estimated Year [2026] USD 1.15 billion
Forecast Year [2032] USD 1.52 billion
CAGR (%) 4.76%

A strategic introduction to human rabies vaccines highlighting clinical urgency, recent technological advances, and the policy priorities that shape stakeholder decision-making

Human rabies vaccines remain a cornerstone of global public health interventions against a disease that is nearly always fatal once clinical signs appear. Advances in immunology, manufacturing platforms, and administration techniques have improved vaccine safety profiles and logistical feasibility, yet persistent gaps in access, awareness, and cold chain infrastructure create uneven protection across geographies. The clinical imperative is clear: prevention through vaccination and timely post-exposure prophylaxis is the most effective means to avert mortality and limit transmission.

Stakeholders across research, clinical practice, policy, and commercial operations must reconcile short-term programmatic needs with long-term ambitions for universal access. Recent technological innovations, including cell-culture-derived antigens and dose-sparing intradermal schedules, offer pathways to expand reach while containing costs. At the same time, regulatory harmonization and strengthened surveillance systems are essential to translate scientific advances into scalable public health outcomes. This introduction frames the subsequent analysis by underscoring where clinical urgency, scientific opportunity, and strategic action intersect to shape decisions across the vaccine lifecycle.

How scientific innovation, delivery optimization, and cross-sector partnerships are reshaping the global human rabies vaccine landscape and programmatic priorities

The landscape for human rabies vaccines is undergoing transformative shifts driven by scientific innovation, programmatic optimization, and evolving delivery ecosystems. Novel manufacturing approaches and improvements in cell substrate technologies have reduced reactogenicity and enabled more consistent antigen quality, which, coupled with enhanced regulatory frameworks, has accelerated approval pathways in several jurisdictions. Concurrently, adoption of intradermal administration and dose-sparing schedules is reshaping immunization programs by improving cost-efficiency and increasing the number of individuals who can be protected with the same supply base.

Market dynamics are also influenced by shifts in procurement strategies and public-private collaborations that aim to secure stable supply lines while incentivizing manufacturing scale-up. Integration of vaccine delivery with broader One Health initiatives and targeted awareness campaigns has strengthened the interface between animal rabies control programs and human prophylaxis efforts, creating synergistic opportunities to reduce incidence. These shifts are creating a more resilient and adaptable ecosystem, but sustainable progress depends on aligning manufacturing capacity, distribution innovations, and cross-sector policy commitments to ensure equitable access.

Assessing how 2025 US tariff changes influence supply chains, procurement strategies, and manufacturing localization decisions for human rabies vaccines

Recent tariff discussions and trade policy adjustments in the United States for 2025 have introduced new considerations for the production, procurement, and distribution of human rabies vaccines. Tariffs can affect downstream costs for imported raw materials, biologics, and finished vaccines, which in turn influence procurement strategies for public health buyers and private distributors. When tariffs increase input costs, manufacturers may adjust sourcing strategies, pursue greater localization of key production stages, or renegotiate supplier arrangements to protect margins and maintain supply reliability.

These trade measures also have implications for inventory planning and contractual risk allocation. Health systems and procurement agencies may lengthen lead times, diversify supplier bases, or increase buffer stocks to mitigate potential price volatility and delivery delays. For multinational manufacturers, tariff-driven cost pressures can accelerate onshoring investments or strategic partnerships with local contract manufacturing organizations to reduce exposure to cross-border levies. At the policy level, stakeholders may engage in advocacy to minimize trade barriers for essential biologics, emphasizing public health imperatives and the potential downstream costs of disrupted prophylaxis availability. Overall, tariff dynamics underscore the need for proactive supply chain risk management and flexible procurement frameworks to ensure continuity of access to rabies vaccines.

Segment-driven insights across vaccine types, classes, administration routes, formulations, end users, and distribution channels that shape clinical adoption and commercial strategy

Segment-specific insights reveal differentiated demand drivers, clinical considerations, and commercial pathways across vaccine types, classes, administration routes, formulations, end users, and distribution channels. Analysis by Vaccine Type shows distinct operational dynamics between post-exposure prophylaxis and pre-exposure prophylaxis: post-exposure programs prioritize rapid access, emergency logistics, and integration with wound care and immunoglobulin therapies, whereas pre-exposure programs emphasize targeted outreach to high-risk populations and occupational immunization scheduling. When considered by Vaccine Class, differences between Human Diploid Cell, Purified Chick Embryo Cell, and Purified Vero Cell vaccines have implications for tolerability, production scalability, and regulatory familiarity in various regions, shaping adoption curves and procurement preferences.

Route of Administration segmentation between intradermal and intramuscular approaches highlights trade-offs in dose efficiency, training requirements, and programmatic acceptance; intradermal strategies can enable dose-sparing but require provider proficiency and sometimes regulatory endorsement. Formulation distinctions between liquid and lyophilized presentations influence cold chain obligations, reconstitution practices, and vial-sharing strategies in clinic workflows. End User segmentation across clinics, hospitals, and research institutes underscores divergent procurement cycles and clinical protocols; clinics often serve as first responders in community settings, hospitals manage complex exposure cases and inpatient prophylaxis, and research institutes drive innovation and clinical evaluation. Distribution Channel segmentation among hospital pharmacies, online pharmacies, and retail pharmacies affects accessibility and last-mile delivery considerations, with each channel presenting unique regulatory and logistics implications. Together, these segment lenses enable nuanced program design and targeted commercial approaches that reflect clinical needs and operational realities.

Regional variations in epidemiology, regulatory frameworks, and delivery capacities that dictate differentiated strategies for vaccine deployment across major geographies

Regional dynamics create important variations in disease burden, regulatory pathways, and delivery system capabilities that inform strategic priorities for vaccine deployment. In the Americas, public health programs and national immunization schedules often prioritize rapid response capacity and integration with emergency services, while procurement frameworks vary between centralized government tenders and decentralized health systems, affecting how suppliers engage and contract. In Europe, Middle East & Africa, regulatory harmonization efforts coexist with diverse infrastructure maturity; some markets have advanced cold chain networks and pharmacovigilance systems, while others require investment in training and last-mile logistics to expand coverage.

Across the Asia-Pacific region, a combination of high-risk populations, evolving manufacturing bases, and policy focus on disease elimination drives interest in both scalable production and innovative delivery models. Regional financing mechanisms and bilateral partnerships frequently support capacity building, surveillance strengthening, and public awareness campaigns. These geographic distinctions necessitate differentiated market entry, pricing, and stakeholder engagement strategies that align with local epidemiology, regulatory expectations, and health system capabilities, enabling more effective allocation of resources and tailored program design.

How company strategies in manufacturing, clinical development, and service-oriented commercial models are shaping competitive advantage and supply reliability for rabies vaccines

Company-level dynamics are critical to understanding innovation pipelines, manufacturing capacity, and commercial reach within the human rabies vaccine space. Leading players are investing in process improvements, cell-substrate optimization, and quality control systems to enhance yield and product consistency. Strategic alliances between originator manufacturers and regional contract producers are enabling scale-up and faster market entry while managing regulatory acceptance in multiple jurisdictions. Several organizations are also advancing clinical studies to refine dosing regimens and evaluate immunogenicity across demographic groups, addressing both safety considerations and programmatic feasibility.

Competitive positioning increasingly reflects capabilities beyond the vial, encompassing training programs for intradermal administration, cold chain support initiatives, and digital tools for adverse event reporting and inventory management. In parallel, companies that can demonstrate reliability of supply, robust pharmacovigilance, and collaborative procurement approaches often secure longer-term institutional relationships. These dynamics favor organizations with integrated commercial models that combine manufacturing excellence, regulatory expertise, and proactive engagement with public health purchasers and clinical networks.

Practical and prioritized recommendations for manufacturers, procurers, and public health leaders to strengthen supply resilience, program efficiency, and equitable access to rabies vaccines

Industry leaders should prioritize actions that strengthen supply resilience, enhance programmatic efficiency, and accelerate equitable access to human rabies vaccines. First, investing in manufacturing redundancy and regional production partnerships will reduce exposure to trade-related cost shocks and improve lead-time predictability. Second, strengthening provider training for dose-sparing intradermal administration and harmonizing clinical guidelines across jurisdictions can expand reach while managing consumable utilization and cold chain load. Third, commercial teams should pursue collaborative procurement agreements with public health agencies and pooled purchasing mechanisms to stabilize demand and enable longer-term capacity investments.

Additionally, companies and public health institutions should deepen engagement with One Health initiatives to synchronize animal rabies control and human prophylaxis efforts, thereby amplifying impact. Investing in digital inventory and pharmacovigilance tools will improve responsiveness and build trust with regulators and buyers. Finally, scenario-based supply chain planning that explicitly accounts for tariff variability, raw material constraints, and geopolitical disruptions will position organizations to respond swiftly to emergent risks while sustaining program continuity and stakeholder confidence.

A rigorous, multi-source research methodology combining expert interviews, regulatory review, and operational case analysis to produce actionable insights for decision-makers

The research underpinning this executive summary combines primary stakeholder interviews, peer-reviewed scientific literature, regulatory documents, and operational case studies to create a multi-dimensional evidence base. Primary consultations included clinical experts, supply chain managers, procurement officials, and commercial leaders to capture frontline operational realities, clinical preferences, and contracting practices. Secondary sources comprised regulatory guidelines, technical monographs on vaccine production, and published studies on dosing strategies and immunogenicity, which were synthesized with programmatic experience from diverse health systems.

Analytical methods integrated qualitative thematic analysis with comparative policy review to surface operational constraints and strategic levers. Risk and sensitivity assessments were used to explore implications of trade policy shifts, manufacturing localization decisions, and administration-route adoption. Throughout the research process, data integrity checks and cross-validation against independent clinical and regulatory sources ensured that findings reflect established science and practical program considerations, enabling robust, actionable insights for decision-makers.

A concise conclusion synthesizing scientific progress, programmatic priorities, and strategic imperatives to accelerate effective rabies prevention and control efforts

This executive summary synthesizes key considerations for stakeholders engaged in the prevention and management of human rabies through vaccination strategies. Scientific advances and delivery innovations present clear opportunities to expand access, but realizing those gains requires coordinated action across manufacturing, procurement, and clinical practice. Tariff and trade considerations underscore the fragility of global supply networks and the importance of risk-aware sourcing and regional production collaboration. Segment-focused analysis highlights how clinical protocols, formulation choices, and distribution channels interact to shape programmatic feasibility and uptake.

For leaders in public health and commercial operations, the path forward involves aligning technical innovation with pragmatic program design, investing in provider training and supply resilience, and pursuing partnerships that synchronize animal and human health objectives. By adopting these integrated approaches, stakeholders can improve prophylaxis availability, enhance response capacity to exposures, and contribute to broader goals of rabies prevention and control across diverse health system contexts.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Rabies Vaccines Market, by Vaccine Type

  • 8.1. Post Exposure Prophylaxis
  • 8.2. Pre Exposure Prophylaxis

9. Human Rabies Vaccines Market, by Vaccine Class

  • 9.1. Human Diploid Cell
  • 9.2. Purified Chick Embryo Cell
  • 9.3. Purified Vero Cell

10. Human Rabies Vaccines Market, by Route Of Administration

  • 10.1. Intradermal
  • 10.2. Intramuscular

11. Human Rabies Vaccines Market, by Formulation

  • 11.1. Liquid
  • 11.2. Lyophilized

12. Human Rabies Vaccines Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Human Rabies Vaccines Market, by End User

  • 13.1. Clinics
  • 13.2. Hospitals
  • 13.3. Research Institutes

14. Human Rabies Vaccines Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Human Rabies Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Human Rabies Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Human Rabies Vaccines Market

18. China Human Rabies Vaccines Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Bavarian Nordic A/S
  • 19.6. Beijing Minhai Biotechnology Co., Ltd.
  • 19.7. Bharat Biotech International Limited
  • 19.8. Bio-Med Pvt. Ltd.
  • 19.9. Cadila Healthcare Ltd.
  • 19.10. Changchun Institute of Biological Products Co., Ltd.
  • 19.11. Chengda Biotechnology Co., Ltd.
  • 19.12. China National Pharmaceutical Group Co., Ltd.
  • 19.13. GlaxoSmithKline plc
  • 19.14. Hualan Biological Engineering Inc.
  • 19.15. Indian Immunologicals Limited
  • 19.16. Medigen Biotechnology Corporation
  • 19.17. Merck & Co., Inc.
  • 19.18. Novartis AG
  • 19.19. PT Bio Farma (Persero) Tbk
  • 19.20. Sanofi SA
  • 19.21. Serum Institute of India Pvt. Ltd.
  • 19.22. Shenzhen Kangtai Biological Products Co., Ltd.
  • 19.23. Sinovac Biotech Ltd.
  • 19.24. Valneva SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN RABIES VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMAN RABIES VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY POST EXPOSURE PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY POST EXPOSURE PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY POST EXPOSURE PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PRE EXPOSURE PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PRE EXPOSURE PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PRE EXPOSURE PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HUMAN DIPLOID CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HUMAN DIPLOID CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HUMAN DIPLOID CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PURIFIED CHICK EMBRYO CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PURIFIED CHICK EMBRYO CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PURIFIED CHICK EMBRYO CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PURIFIED VERO CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PURIFIED VERO CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY PURIFIED VERO CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. GCC HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. GCC HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. GCC HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 123. GCC HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. GCC HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. G7 HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. G7 HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. G7 HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 144. G7 HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. G7 HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NATO HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. NATO HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. NATO HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 151. NATO HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. NATO HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL HUMAN RABIES VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA HUMAN RABIES VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY VACCINE CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA HUMAN RABIES VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)